

A Information

- A.1 Empty Chapter
- A.2 Empty Chapter
- A.3 List of Abbreviations
- A.4 Glossary
- A.5 Adress-Register
- A.6 References

B Japanese Regulations

- B.1 MHW Ministerial Ordinance No. 2,1961:
Regulations for Buildings and Facilities of Pharmacies, etc.
- B.2 MHLW Ministerial Ordinance No. 136,2004 :
Standards for Quality Assurance for Drugs, Quasi-drugs, Cosmetics and
Medical Devices
- B.3 MHLW Ministerial Ordinance No. 179, 2004:
Standards for Manufacturing Control and Quality Control for Drugs and
Quasi-drugs

C EU Directives and Guidelines

- C.1 EU GMP Guide: Introduction
- C.2 Commission Directive 2003/94/EC
- C.3 Commission Directive 91/412/EEC
- C.4 Part I
Basic Requirements for Medicinal Products
 - C.4.1 Chapter 1:
Quality Management
 - C.4.2 Chapter 2:
Personnel
 - C.4.3 Chapter 3:
Premises and Equipment
 - C.4.4 Chapter 4:
Documentation
 - C.4.5 Chapter 5:
Production

- C.4.6 Chapter 6:
Quality Control
- C.4.7 Chapter 7:
Contract Manufacture and Analysis
- C.4.8 Chapter 8:
Complaints and Product Recall
- C.4.9 Chapter 9:
Self Inspection
- C.5 Part II
Basic Requirements for Active Substances used as Starting Materials
- C.6.1 Annex 1
Manufacture of Sterile Medicinal Products
- C.6.2 Annex 2
Manufacture of Biological Medicinal Products for Human Use
- C.6.3 Annex 3
Manufacture of Radiopharmaceuticals
- C.6.4 Annex 4
Manufacture of Veterinary Medicinal Products other than Immunological
Veterinary Medicinal Products
- C.6.5 Annex 5
Manufacture of Immunological Veterinary Medicinal Products
- C.6.6 Annex 6
Manufacture of Medicinal Gases
- C.6.7 Annex 7
Manufacture of Herbal Medicinal Products
- C.6.8 Annex 8
Sampling of Starting and Packaging Materials
- C.6.9 Annex 9
Manufacture of Liquids, Creams and Ointments
- C.6.10 Annex 10
Manufacture of Pressurised Metered Dose Aerosol Preparations for
Inhalation
- C.6.11 Annex 11
Computerised Systems
- C.6.12 Annex 12
Use of Ionising Radiation in the Manufacture of Medicinal Products

- C.6.13 Annex 13
Investigational Medicinal Products
- C.6.14 Annex 14
Manufacture of Medicinal Products Derived from Human Blood or Plasma
- C.6.15 Annex 15
Qualification and Validation
- C.6.16 Annex 16
Certification by a Qualified Person and Batch Release
- C.6.17 Annex 17
Parametric Release
- C.6.18 Annex 18
Good Manufacturing Practice for Active Pharmaceutical Ingredients
- C.6.19 Annex 19
Reference and Retention Samples
- C.6.20 Annex 20
Quality Risk Management
- C.7 Glossary
- C.8 Part III
- C.8.1 Explanatory Notes on the preparation of a Site Master File
- C.9 Note For Guidance on Quality of Water for Pharmaceutical Use
- C.10 Compilation of Community Procedures on Inspections and Exchange of Information

D USA: CFR and FDA Guidelines

- D.1 Code of Federal Regulations
- D.2 Guidance for Industry
Process Validation: General Principles and Practices
- D.3 Guide to Inspections of High Purity Water Systems
- D.4 Guide to Inspections of Validation of Cleaning Processes
- D.5 Guide to inspections of oral solid dosage forms pre/post approval issues for development and validation
- D.6 Guide to Inspections of Validation Documentation
- D.7 Guide to Inspections:
Computerized Systems in Drug Establishments (2/83)

- D.8 Guide to Inspections of Pharmaceutical Quality Control Laboratories
- D.9 Guidance for Industry:
Investigating Out-of-Specification (OOS)
Test Results for Pharmaceutical Production
- D.10 Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing – Current Good
Manufacturing Practice
- D.11 Guidance for Industry
PAT – A Framework for Innovative Pharmaceutical Development,
Manufacturing, and Quality Assurance
- D.12 Guidance for Industry
Part 11, Electronic Records; Electronic Signatures – Scope and Application
- D.13 21 CFR Part 820 – Quality System Regulation
- D.14 Guidance for Industry
Quality Systems Approach to Pharmaceutical CGMP Regulations
- D.15 Guidance for Industry
cGMP for Phase 1 Investigational Drugs
- D.16 Federal Food, Drug, and Cosmetic Act (FD&C Act)
- D.17 Pre-Approval Inspections

E ICH-Guidelines

- E.1.A ICH Q1A(R2):
Stability Testing of New Drug Substances and Products
- E.1.B ICH Q1B:
Stability Testing: Photostability Testing of New Drug Substances and
Products
- E.1.C ICH Q1C:
Stability Testing for New Dosage Forms
- E.1.D ICH Q1D:
Bracketing and Matrixing Designs for Stability Testing of New Drug
Substances and Products
- E.1.E ICH Q1E:
Evaluation of Stability Data
- E.2 ICH Q2(R1):
Validation of Analytical Procedures:
Text and Methodology

- E.3.A ICH Q3A(R2):
Impurities in New Drug Substances
- E.3.B ICH Q3B(R2):
Impurities in New Drug Products
- E.3.C ICH Q3C(R5):
Impurities: Guideline for Residual Solvents
- E.4 ICH Q4:
Pharmacopoeias
- E.4.A ICH Q4A:
Pharmacopoeial Harmonisation
- E.4.B ICH Q4B:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
- E.4.B.1 ICH Q4B Annex 1:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Residue on Ignition/Sulphated Ash – General Chapter
- E.4.B.2 ICH Q4B Annex 2:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Extractable Volume of Parenteral Preparations – General Chapter
- E.4.B.3 ICH Q4B Annex 3:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Particulate Contamination: Sub-Visible Particles – General Chapter
- E.4.B.4.1 ICH Q4B Annex 4A:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Microbiological Examination of Non-Sterile Products: Microbial Enumerations Tests – General Chapter
- E.4.B.4.2 ICH Q4B Annex 4B :
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Microbiological Examination of Non-Sterile Products: Test for Specified Micro-Organisms – General Chapter

- E.4.B.4.3 ICH Q4B Annex 4C:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Microbiological Examination
of Non-Sterile Products: Acceptance Criteria For Pharmaceutical
Preparations and Substances for Pharmaceutical Use –
General Chapter**
- E.4.B.5 ICH Q4B Annex 5:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Disintegration Test –
General Chapter**
- E.4.B.6 ICH Q4B Annex 6:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Uniformity of Dosage Units –
General Chapter**
- E.4.B.7 ICH Q4B Annex 7:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Dissolution Test –
General Chapter**
- E.4.B.8 ICH Q4B Annex 8:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Sterility Test –
General Chapter**
- E.4.B.9 ICH Q4B Annex 9:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Tablet Friability –
General Chapter**
- E.4.B.10 ICH Q4B Annex 10:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Polyacrylamide Gel Electrophoresis
– General Chapter**
- E.5.A ICH Q5A(R1):
Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of
Human or Animal Origin**
- E.5.B ICH Q5B:
Quality of Biotechnological Products: Analysis of the Expression Construct
in Cells Used for Production of R-DNA Derived Protein Products**
- E.5.C ICH Q5C:
Quality of Biotechnological Products: Stability Testing of Biotechnological/
Biological Products**

- E.5.D** ICH Q5D:
Derivation and Characterisation of Cell Substrates used for Production of Biotechnological/Biological Products
- E.5.E** ICH Q5E:
Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process
- E.6.A** ICH Q6A:
Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
- E.6.B** ICH Q6B:
Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
- E.7** ICH Q7:
Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
- E.7.1** "How to do" Document –
Interpretation of the ICH Q7a Guide
- E.8** ICH Q8 (R2):
Pharmaceutical Development
- E.9** ICH Q9:
Quality Risk Management
- E.10** ICH Q10:
Pharmaceutical Quality System
- E.10.1** Quality Implementation Working Group
on Q8, Q9 and Q10
Questions & Answers
- F** **PIC/S Guidelines**
- F.1** PIC/S PI 006-3:
Recommendations on Validation Master Plan
Installation and Operational Qualification
Non-Sterile Process Validation
Cleaning Validation
- F.2** PIC/S PI 007-5:
Recommendation on the Validation of Aseptic Processes
- F.3** PIC/S PI 011-3:
Good Practices for
Computerised Systems in Regulated "GXP" Environments

- F.4 PIC/S PI 023-2:
Aide-mémoire
Inspection of Pharmaceutical Quality Control Laboratories
- F.5 PIC/S PE 008-4:
Explanatory notes
for pharmaceutical manufacturers on the preparation of a Site Master File
- F.6 PIC/S PI 009-3:
Aide-mémoire
Inspection of Utilities
- F.7 PIC/S PI 028-1:
Aide-mémoire
GMP Inspection Related to Packaging
- F.8 PIC/S PI 032-2:
Recommendation
GMP Annex 1 Revision 2008,
Interpretation of Most Important Changes for the Manufacture of Sterile
Medicinal Products

G GMP of other Regions

This chapter is supplied on CD-ROM and online (www.gmp-manual.com) only.

- G.1 WHO Guidelines
 - G.1.1 Quality assurance of pharmaceuticals
 - G.1.1.1 1. WHO good manufacturing practices: main principles for pharmaceutical products
 - G.1.1.2 2. WHO good manufacturing practices: starting materials
 - G.1.1.3 3. WHO good manufacturing practices: specific pharmaceutical products
 - G.1.1.4 4. Inspection
 - G.1.1.5 5. Hazard and risk analysis in pharmaceutical products
 - G.1.1.6 6. Sampling operations
 - G.1.2 Guide to good storage practices for pharmaceuticals
 - G.1.3 Annex 5
WHO good distribution practices for pharmaceutical products
- G.2 Canada
Good Manufacturing Practices (GMP) Guidelines – 2009 Edition
(GUI-0001)

- G.2.1** **Annex 1**
to the Current Edition of the Good Manufacturing Practices Guidelines –
Selected Category IV Monograph Drugs
(GUI-0066)
- G.2.2** **Annex 2**
to the Current Edition of the Good Manufacturing Practices Guidelines –
Schedule D Drugs, Biological Drugs Including Fractionated Blood Products
(GUI-0027)
- G.2.3** **Annex 3**
to the Current Edition of the Good Manufacturing Practices Guidelines –
Schedule C Drugs
(GUI-0026)
- G.2.4** **Annex 4**
to the Current Edition of the Good Manufacturing Practices Guidelines –
Veterinary Drugs
(GUI-0012)
- G.2.5** **Annex 5**
to the Current Edition of the Good Manufacturing Practices Guidelines –
Positron Emitting Radiopharmaceuticals (PER's)
(GUI-0071)
- G.2.6** **Annex 13**
to the Current Edition of the Good Manufacturing Practices Guidelines –
Drugs Used in Clinical Trials
(GUI-0036)
- G.2.7** **Annex 14**
to the Current Edition of the Good Manufacturing Practices Guidelines –
Schedule D Drugs, Human Blood and Blood Components
(GUI-0032)